XT
MLTX icon

XTX Topco’s MoonLake Immunotherapeutics MLTX Stock Holding History

XTX Topco’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Buy
112,044
+89,071
+388% +$1.48M 0.04% 804
2025
Q4 		$303K Sell
22,973
-9,272
-29% -$109K 0.01% 2056
2025
Q3 		$231K Buy
+32,245
New +$1.68M 0.01% 1725
2025
Q2 		– Sell
-8,495
Closed -$332K – 2867
2025
Q1 		$332K Buy
+8,495
New +$366K 0.02% 1324

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco's MLTX Position: Q1 2026 in Review

XTX Topco increased its MoonLake Immunotherapeutics (MLTX) stake by 388% in Q1 2026, buying an estimated $1.48M and bringing the position to 112,044 shares worth $2.09M. The position accounts for 0.04% of the portfolio, ranked #804.

XTX Topco first reported a position in MLTX in Q1 2025 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • XTX Topco held 112,044 shares of MoonLake Immunotherapeutics worth $2.09M as of Q1 2026.
  • XTX Topco bought 89,071 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.48M.
  • MoonLake Immunotherapeutics made up 0.04% of XTX Topco's portfolio in Q1 2026, its #804 holding.
  • XTX Topco first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.